Galectin Therapeutics Inc. (GALT)

[jmh0602]

"This trial was designed and is being conducted with a primary endpoint that the U.S. Food and Drug Administration views may be a surrogate for outcomes for registration trials in this patient population."
Does this mean possible approval by the FDA, as in the phase 2 results can be a surrogate for phase 3 trials, thus eliminating the need for further trials? So if the results are outstanding galt could be first to market for nash in six months, and the stock is struggling to keep an 80 million market cap. Maybe the market just doesn't believe results will be positive after the lumps taken in phase 1, cohort 2 and the fox trials. Well, all the chips are on the table, all or nothing in 6 months.